OSR Health (OSRHW) Non-Current Deffered Revenue (2023 - 2024)
OSR Health (OSRHW) posted Non-Current Deffered Revenue of $2.1 million for Q4 2024, little changed sequentially from $2.1 million in Q3 2024, and little changed YoY from $2.1 million in Q1 2024.
OSR Health (OSRHW) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends
OSR Health has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $2.1 million in Q4 2024.
- Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.1 million (changed 0.0% YoY) and the FY2024 annual result came in at $2.1 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue steadied at $2.1 million in Q4 2024 per OSRHW's latest filing, from $2.1 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.1 million in Q1 2023 and troughed at $2.1 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | - |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | - |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.07 Mn |
| Sep 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 2.07 Mn |
| Mar 31, 2023 | 2.07 Mn |